-
Nov 4, 2024 | 
targetedonc.com | Abdulraheem Yacoub
Abdulraheem Yacoub, MD, professor of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center, discusses the adverse event (AE) profile of imetelstat (Rytelo) when treating patients with myelodysplastic syndromes (MDS). The phase 3 IMerge trial (NCT02598661) led to this drug’s approval in patients with low- and intermediate-1 risk MDS and transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks.
-
Oct 15, 2024 | 
targetedonc.com | Abdulraheem Yacoub
Abdulraheem Yacoub, MD, professor of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center, discusses imetelstat (Rytelo) as a newer and exciting option for patients with myelodysplastic syndromes (MDS). In low- and intermediate-1 risk MDS and transfusion-dependent anemia, Yacoub says imetelstat offers a significant improvement in a population with limited effective treatments.
-
Aug 14, 2024 | 
targetedonc.com | Abdulraheem Yacoub
2 Commerce Drive Cranbury, NJ 08512
-
Aug 14, 2024 | 
targetedonc.com | Abdulraheem Yacoub
2 Commerce Drive Cranbury, NJ 08512
-
May 10, 2024 | 
patientpower.info | Abdulraheem Yacoub
Disclaimer: To protect patient privacy, this question has been edited slightly to omit identifying details. A Patient Power user who attended the event, Answers Now: Managing Polycythemia Vera Symptoms (patientpower.info), asked, “I have polycythemia vera (PV), and I want to know: is it hereditary?
-
Apr 29, 2024 | 
patientpower.info | Lori Futcher |Abdulraheem Yacoub |Selina Gierer
In this on-demand segment from our recent Systemic Mastocytosis Evening With the Docs program, patient host Lori Futcher talks with Abdulraheem Yacoub, MD, and Selina Gierer, DO, from The University of Kansas Health. The discussion centers around the most common symptoms of systemic mastocytosis. What role do diet or environmental factors play? Support for this series has been provided by Blueprint Medicines.
-
Nov 17, 2023 | 
targetedonc.com | Abdulraheem Yacoub
Clinical Experiences With Momelotinib for Patients With MyelofibrosisDr Abdulraheem Yacoub discusses experience with the JAK inhibitor momelotinib in patients with myelofibrosis, noting robust efficacy in clinical trials for spleen volume reduction, symptom improvement, and anemia benefit, but explains that its utility in first-line versus second-line settings is still being determined.
-
Nov 17, 2023 | 
targetedonc.com | Abdulraheem Yacoub
Currently Available Treatment Options for Patients With MyelofibrosisAbdulraheem Yacoub, MD, reviews the current myelofibrosis treatment landscape including the four approved JAK inhibitors - ruxolitinib, fedratinib, pacritinib, and momelotinib - discussing the clinical trial data and indications for each in first-line and second-line settings.
-
Nov 10, 2023 | 
targetedonc.com | Abdulraheem Yacoub
Treatment Goals for Patients With MyelofibrosisTreatment goals for patients with myelofibrosis include prolonged survival and improved quality of life, with decision-making incorporating risk level, transplant eligibility, toxicity, and clinical trial data to select among the available JAK inhibitors.
-
Nov 10, 2023 | 
targetedonc.com | Abdulraheem Yacoub
Diagnosis and Risk Stratification of MyelofibrosisAbdulraheem Yacoub, MD, provides an overview of myelofibrosis, including diagnosis via bone marrow examination, clinical criteria, and risk stratification using prognostic models to determine appropriate therapy.
